产地国家：日本 处 方 药：是 所属类别：15毫克/片 140片/盒 包装规格：15毫克/片 140片/盒 计价单位：盒 生产厂家中文参考译名: Bayer Yakuhin, Ltd 生产厂家英文名: Bayer Yakuhin, Ltd 原产地英文商品名: Xarelto(イグザレルト錠)15mg/Tablets 140Tablets/box 原产地英文药品名: Rivaroxaban 中文参考商品译名: Xarelto(イグザレルト錠)15毫克/片 140片/盒 中文参考药品译名: 利伐沙班

简介：

部份中文利伐沙班处方资料(仅供参考) 商品名：Xarelto Tablets 英文名：Rivaroxaban 中文名：利伐沙班片 生产商：拜耳制药 イグザレルト錠10mg/イグザレルト錠15mg 药用类别名称 选择性直接作用XA型抑制剂 批准日期：2012年4月 商標名 Xarelto Tablets 10mg Xarelto Tablets 10mg 構造式 一般名 リバーロキサバン(Rivaroxaban)JAN (rivaroxaban)INN 化学名 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl｝methyl)thiophene-2-carboxamide 分子式 C19H18ClN3O5S 分子量 435.88 性状： 本产品为白色至小黄色粉末。 本品微溶于 N、n-二甲基甲酰胺、二甲基亚硫酸或 n-甲基吡咯烷酮, 几乎不溶于乙腈, 很溶于乙醇 (99.5), 几乎不溶于水。 药用药理学 1. 作用机制 该制剂是一种选择性的直接因子 Xa 抑制剂, 显示了口服药物的效果。 该制剂抑制内源性和外源性凝血级联中的因子Xa, 抑制凝血酶的产生和血栓形成。这种药物不抑制凝血酶, 对血小板没有直接影响。 2. 抗血栓作用 在小鼠、大鼠或家兔的静脉和动脉血栓形成模型中, 该药物以剂量依赖性的形式抑制血栓形成。在兔静脉血栓形成的情况下, 血栓形成后的血块被抑制。 适应症 非瓣膜性心房颤动患者缺血性脑卒中及全身栓塞的抑制 用法与用量 在成人中, 每天口服15毫克。 对于肾功能损害的患者, 有必要将肾功能的程度降低到10mg1 天。 包装 片剂 10毫克 PTP 包装100片(10片x10), 140片(14片x10), 500片(10片x50) * 玫瑰包装500片 15mg PTP 包装100片(10片x10), 140片(14片x10), 500片(10片x50) * 瓶子包装500片 制造 拜耳公司 注：以上中文不够完整，使用者以原处方资料为准。 英文说明书： Xarelto Tablets 10mg [prevention of onset of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation](イグザレルト錠10mg[非弁膜症性心房細動患者における虚血性脳卒中および全身性塞栓症の発症抑制]) Brand name : Xarelto Tablets 10mg [prevention of onset of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation] Active ingredient: Rivaroxaban Dosage form: pale red tablet, diameter: 6 mm, thickness: 2.8 mm Print on wrapping: (face) イグザレルト10mg, ▽10 (back) Xarelto 10mg Effects of this medicine This medicine inhibits blood coagulation factor Xa to prevent blood clotting. It improves clotting tendency and treats or prevents thromboembolism, a disease caused by blood coagulation in the vessels It is usually used for treatment and prevention of recurrence of deep-vein thrombosis and pulmonary thromboembolism. Before using this medicine, be sure to tell your doctor and pharmacist •If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines. If you have bleeding (intracranial bleeding, gastrointestinal bleeding, etc.), liver disorder, renal disorder, acute bacterial endocarditis, bleeding tendency, prolonged bleeding or low body weight. If you are at high risk of bleeding (If you have recently had gastrointestinal tract ulcer, intracranial bleeding or cerebrospinal/eye surgery. If you have a history of bronchiectasis or lung bleeding. If you have gastric ulcer, duodenal ulcer, malignant tumor or hypertension). •If you are pregnant, possibly pregnant or breastfeeding. •If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) Dosing schedule (How to take this medicine) •Your dosing schedule prescribed by your doctor is << to be written by a healthcare professional>> •In general, for adults, take 15 mg of the active ingredient at a time, twice a day after meals for the first 3 weeks. Subsequently, take 15 mg of the active ingredient at a time, once a day. This preparation contains 15 mg of the active ingredient in a tablet. Strictly follow the instructions. •For the first 3 weeks (1 tablet at a time, twice a day): If you miss a dose, take a missed dose as soon as possible. If you remember the missed dose at the time of the next dose, take two doses at one time and follow your regular dosing schedule. After the first 3 weeks (1 tablet at a time, once a day): If you miss a dose, take a missed dose as soon as possible. However, there should be 12 hours or more before the next scheduled dose. You should never take two doses at one time. •If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist. •Do not stop taking this medicine unless your doctor instructs you to do so. Precautions while taking this medicine •If you will receive dental treatment, endoscopic examination or surgery, make sure to inform your doctor in advance that you are taking this medicine. If you will receive treatment in other medical institutions or buy other medicines at pharmacies, etc., inform your doctor or pharmacist that you are taking this medicine. •Pay attention not to get injured since this medicine lead to prolonged bleeding. If bleeding time is prolonged or the injury involves a large area, immediately contact your doctor. Pay extra attention for the first 3 weeks (1 tablet at a time, twice a day). •Avoid taking any food containg hypericum perforatum (St. John's wort), since it may diminish medicinal effects. Possible adverse reactions to this medicine The most commonly reported adverse reactions include subcutaneous bleeding, nasal bleeding and bloody stool. If any of these symptoms occur, consult with your doctor or pharmacist. The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately. •nausea, vomiting, headache [bleeding (gastrointestinal bleeding, intracranial bleeding, etc.)] •nausea, dull, yellowing of the skin and the white of eyes [liver dysfunction, jaundice] •coughing, bloody phlegm, breathing difficulty, shortness of breath, fever [interstitial lung disease] The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above. Storage conditions and other information •Keep out of the reach of children. Store away from direct sunlight, heat and moisture. •Discard the remainder. Do not store them. Bayer Yakuhin, Ltd.Internal The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.